Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi

Journal of Clinical Microbiology

Volumn 46, Issue 12, 2008, Pages 4071-4074

  Maida, Carmelo Massimo ^a   Milici, Maria Eleonora ^a   Trovato, Laura ^b   Oliveri, Salvatore ^b   Amodio, Emanuele ^a   Spreghini, Elisabetta ^c   Scalise, Giorgio ^c   Barchiesi, Francesco ^c  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; BROTH DILUTION; CANDIDA KRUSEI; CONTROLLED STUDY; DISK DIFFUSION; FUNGUS ISOLATION; INTERMETHOD COMPARISON; MOULD; NONHUMAN; PRIORITY JOURNAL; SCOPULARIOPSIS BREVICAULIS;

ANTIFUNGAL AGENTS; ECHINOCANDINS; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES;

FUNGI;

EID: 57349131039     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01088-08     Document Type: Article

References (28)

1. Arikan, S., and J. H. Rex. 2000. New agents for treatment of systemic fungal infections. Emerg. Drugs 5:135-160.
2. Arikan, S., V. Paetznick, and J. H. Rex. 2002. Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 46:3084-3087.
3. Denning, D. W. 1998. Invasive aspergillosis. Clin. Infect. Dis. 26:781-803.
4. Denning, D. W. 2002. Echinocandins: a novel class of antifungal. J. Clin. Chemother. 49:889-891.
5. De Pauw, B., T. J. Walsh, J. P. Donnelly, D. A. Stevens, J. E. Edwards, T. Calandra, P. G. Pappas, J. Maertens, O. Lortholary, C. A. Kauffman, D. W. Denning, T. F. Patterson, G. Maschmeyer, J. Bille, W. E. Dismukes, R. Herbrecht, W. W. Hope, C. C. Kibbler, B. J. Kullberg, K. A. Marr, P. Muñoz, F. C. Odds, J. R. Perfect, A. Restrepo, M. Ruhnke, B. H. Segal, J. D. Sobel, T. C. Sorrell, C. Viscoli, J. R. Wingard, T. Zaoutis, J. E. Bennett, et al. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
6. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new trizole SCH 56592 and the echinocandins MK-0991 (L-743,872) and LY 303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
7. Espinel-Ingroff, A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20:121-136.
8. Espinel-Ingroff, A., B. Arthington-Skaggs, N. Iqbal, D. Ellis, M. A. Pfaller, S. Messer, M. Rinaldi, A. Fothergill, D. L. Gibbs, and A. Wang. 2007. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J. Clin. Microbiol. 45:1811-1820.
9. Jones, R. N., J. T. Kirby, S. A. Messer, and D. J. Sheehan. 2007. Development of anidulafungin for disk diffusion susceptibility testing against Candida spp. Diagn. Microbiol. Infect. Dis. 58:371-374.
10. Lozano-Chiu, M., P. W. Nelson, V. L. Paetznick, and J. H. Rex. 1999. Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991. J. Clin. Microbiol. 37:1625-1627.
11. Marr, K. A., R. A. Carter, F. Crippa, A. Wald, and L. Corey. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34:909-917.
12. McNeil, M. M., S. L. Nash, R. A. Hajjeh, M. A. Phelan, L. A. Conn, B. D. Plikaytis, and D. W. Warnock. 2001. Trends in mortality due to invasive mycotic disease in the United States, 1980-1997. Clin. Infect. Dis. 33:641-647.
13. Messer, S. A., J. T. Kirby, H. S. Sader, T. R. Fritsche, and R. N. Jones. 2004. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J. Antimicrob. Chemother. 54:1051-1056.
14. Milici, M. E., C. M. Maida, E. Spreghini, B. Ravazzolo, S. Oliveri, G. Scalise, and F. Barchiesi. 2007. Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. J. Clin. Microbiol. 45:3529-3533.
15. Morgan, J., K. A. Wannemuehler, K. A. Marr, S. Hadley, D. P. Kontoyiannis, T. J. Walsh, S. K. Fridkin, P. G. Pappas, and D. W. Warnock. 2005. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med. Mycol. 43(Suppl. 1):S49-S58.
16. NCCLS/CLSI. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS M38-A. National Committee for Clinical Laboratory Standards. Wayne, Pa.
17. NCCLS/CLSI. 2002. Reference method for broth dilution susceptibility testing of yeasts. Approved standard, 2nd ed. M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
18. NCCLS/CLSI. 2004. Method for antifungal disk diffusion susceptibility testing of yeasts. Approved guideline. M44-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
19. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Cantón, M. Cuenca-Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Laverdière, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Pemán, S. Perea, J. R. Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J.-L. Rodriguez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.
20. Patterson, T. F., W. R. Kirkpatrick, M. White, J. W. Hiemenz, J. R. Wingard, B. Dupont, M. G. Rinaldi, D. A. Stevens, and J. R. Graybill. 2000. Invasive aspergillosis: disease spectrum, treatment practices and outcomes. Medicine 79:250-260.
21. Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY 303366 and MK-0991 (L-743,872), against clinical isolates of Aspergillus, Fusarium, Rhizopus and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:251-255.
22. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2005. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol. 43:5425-5427.
23. Ribes, J. A., C. L. Vanover-Sans, and D. J. Baker. 2000. Zygomycetes in human disease. Clin. Microbiol. Rev. 13:236-301.
24. Stevens, D. A., V. L. Kan, M. A. Judson, V. A. Morrison, S. Dummer, D. W. Denning, J. E. Bennett, T. J. Walsh, T. F. Patterson, and G. A. Pankey. 2000. Practice guidelines for disease caused by Aspergillus. Clin. Infect. Dis. 30:696-709.
25. Reference deleted.
26. Walsh, T. J., A. Groll, J. Hiemenz, R. Flemming, E. Roilides, and E. Anaissie. 2004. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. 10:48-66.
27. Walsh, T. J., E. J. Anaissie, D. W. Denning, R. Herbrecht, D. P. Kontoyiannis, K. A. Marr, V. A. Morrison, B. H. Segal, W. J. Steinbach, D. A. Stevens, J. A. van Burik, J. R. Wingard, and T. F. Petterson. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Disease Society of America. Clin. Infect. Dis. 46:327-360.
28. Wiederhold, N. P., L. K. Najvar, R. Bocanegra, D. Molina, M. Olivo, and J. R. Graybill. 2007. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob. Agents Chemother. 51:1616-1620.